International Clinical Trial: Interventional Therapy Combined with Camrelizumab and Apatinib in the Treatment of Intermediate-Advanced Hepatocellular Carcinoma After Progression on First-Line Targeted-Immunotherapy: A Single-Arm, Phase II Clinical Study

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132596) titled 'Interventional Therapy Combined with Camrelizumab and Apatinib in the Treatment of Intermediate-Advanced Hepatocellular Carcinoma After Progression on First-Line Targeted-Immunotherapy: A Single-Arm, Phase II Clinical Study' on Sept. 16.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

Condition: Mid- to Late-Stage Hepatocellular Carcinoma

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-10-23

Target Sample Size: Experimental group:60;

Countri...